CCOAT is a malaria research group within the Division of Clinical Pharmacology, Department of Medicine at the University of Cape Town
Malaria Research
We conduct clinical trials, meta-analyses, malaria drug resistance surveillance and pharmacovigilance activities and support research capacity development in low-resource settings
Treat Malaria and Break Malaria Transmission
This video explains the cycle of malaria infection and transmission and how it can be broken with artemether+lumefantrine and primaquine therapy.
A glimpse into why we do, what we do
Our group aims to lead research that can improve the treatment of malaria in Africa, and globally.
Helping Policy Makers
The CCOAT team is involved on a day-to-day basis in helping to improve malaria medicines. We collaborate with multiple groups in our research to support policy makers with the evidence they need.



CCOAT brings together the expertise of clinical and laboratory researchers, working together to improve malaria treatment. We are the Southern African Centre for the WorldWide Antimalarial Resistance Network (part of the Infectious Diseases Data Observatory) where we also lead the Pharmacology module.

CCOAT has conducted multidisciplinary research in Africa since the late 1990s. Our focus is on research that is essential for improving the availability, dosing and selection of antimalarial drugs.Such research allows for the advancement of national, regional and global malaria elimination goals. We contribute substantially to the evaluation of changes in malaria treatment policy, to the development of new antimalarials, and to dose optimisation (working out how much of the medicine needs to be given in vulnerable populations like young children or pregnant women or people with other diseases like HIV/AIDS, or malnutrition). We also conduct methodological research to help ensure malaria research is conducted in the best way.

Most of the world's malaria deaths occur in Africa and in vulnerable populations, yet most malaria research is led by academics from Europe and North America, and most early drug development studies are conducted in non-African populations. Our group aims to lead research that can improve the better treatment of malaria in Africa, and globally. Together with vector control, better treatments will contribute to the control and eventual elimination of malaria. Drug (and insecticide) resistance are the main obstacles to malaria control to elimination, which South Africa aims optimistically to achieve by 2018. Through our partnerships and collaborations we launched the UCT MRC Collaborating Centre for Optimising Antimalarial Therapy (CCOAT), linking drug discovery by UCT's H3-D initiative, with clinical drug development and field studies aimed at informing national and global malaria treatment guidelines.